Curis to Release Second Quarter 2020 Financial Results and Hold Conference Call on August 4, 2020
Curis, Inc. (NASDAQ: CRIS) will announce its second quarter 2020 financial results on August 4, 2020, after US market close. A conference call is scheduled for the same day at 4:30 p.m. ET, accessible via phone or the company's website. Curis specializes in developing innovative therapeutics for cancer treatment and has ongoing collaborations focusing on immuno-oncology and precision oncology. The company holds exclusive licenses for several drug candidates currently in clinical trials.
- None.
- None.
LEXINGTON, Mass., July 28, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2020 financial results on Tuesday, August 4, 2020, after the close of US markets. Management will host a conference call on the same day at 4:30 p.m. ET.
To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.
About Curis, Inc.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma and in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/curis-to-release-second-quarter-2020-financial-results-and-hold-conference-call-on-august-4-2020-301100826.html
SOURCE Curis, Inc.
FAQ
When will Curis release its second quarter 2020 financial results?
What time is the Curis conference call scheduled for?
How can I access the Curis conference call?
What is Curis's focus in biotechnology?
What collaborations does Curis have in its pipeline?
